Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population.
暂无分享,去创建一个
Hongbing Shen | Q. Wei | Zhibin Hu | G. Jin | Hongxia Ma | Xinru Wang | X. Zhai | Wen-sen Chen | Shui Wang | Xue-chen Wang | J. Qin | Jun Gao | Ji-yong Liu | Q. Wei | Hongxia Ma
[1] T. Rauch,et al. 53BP1 is a Positive Regulator of the BRCA1 Promoter , 2005, Cell cycle.
[2] A. Lambropoulos,et al. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. , 2005, Cancer letters.
[3] P. Bugert,et al. TP53-binding protein variants and breast cancer risk: a case-control study , 2005, Breast Cancer Research.
[4] M. Papa,et al. The R72P P53 mutation is associated with familial breast cancer in Jewish women , 2005, British Journal of Cancer.
[5] Hongbing Shen,et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. , 2004, Oncology reports.
[6] E. Guinó,et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA , 2004, Oncogene.
[7] Jeffrey E. Lee,et al. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. , 2003, The Journal of investigative dermatology.
[8] Peter Donnelly,et al. A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.
[9] T. Eisen,et al. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. , 2003, Mutagenesis.
[10] S. Elledge,et al. Role for the BRCA1 C-terminal Repeats (BRCT) Protein 53BP1 in Maintaining Genomic Stability* , 2003, The Journal of Biological Chemistry.
[11] Junjie Chen,et al. p53 Binding Protein 53BP1 Is Required for DNA Damage Responses and Tumor Suppression in Mice , 2003, Molecular and Cellular Biology.
[12] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.
[13] E. Imyanitov,et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition , 2003, International journal of cancer.
[14] Jiri Bartek,et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer , 2002, Nature Cell Biology.
[15] S. Elledge,et al. 53BP1, a Mediator of the DNA Damage Checkpoint , 2002, Science.
[16] L. Serpell,et al. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor , 2002, The EMBO journal.
[17] D. Spandidos,et al. p53 codon 72 polymorphism and its association with bladder cancer. , 2002, Cancer letters.
[18] M. Spitz,et al. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.
[19] D. Livingston,et al. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. , 2002, Genes & development.
[20] J. Glover,et al. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1 , 2001, Nature Structural Biology.
[21] Shu Ye,et al. PIRA PCR designer for restriction analysis of single nucleotide polymorphisms , 2001, Bioinform..
[22] Junjie Chen,et al. Tumor Suppressor P53 Binding Protein 1 (53bp1) Is Involved in DNA Damage–Signaling Pathways , 2001, The Journal of cell biology.
[23] Y. Adachi,et al. Phosphorylation and Rapid Relocalization of 53BP1 to Nuclear Foci upon DNA Damage , 2001, Molecular and Cellular Biology.
[24] J. Morales,et al. Negative Cell Cycle Regulation and DNA Damage-inducible Phosphorylation of the BRCT Protein 53BP1* , 2001, The Journal of Biological Chemistry.
[25] T. Halazonetis,et al. P53 Binding Protein 1 (53bp1) Is an Early Participant in the Cellular Response to DNA Double-Strand Breaks , 2000, The Journal of cell biology.
[26] B. Gusterson,et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.
[27] T. Halazonetis,et al. p 53 Binding Protein 1 ( 53 BP 1 ) Is an Early Participant in the Cellular Response to DNA Double-Strand Breaks , 2000 .
[28] Miranda Thomas,et al. Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.
[29] R. Gornall,et al. p53 polymorphism and risk of cervical cancer , 1998, The Lancet.
[30] M. Sternberg,et al. Structure of an XRCC1 BRCT domain: a new protein–protein interaction module , 1998, The EMBO journal.
[31] Bin Li,et al. Stimulation of p53-mediated Transcriptional Activation by the p53-binding Proteins, 53BP1 and 53BP2* , 1998, The Journal of Biological Chemistry.
[32] I. Jacobs,et al. p53 codon 72 polymorphism and risk of cervical cancer in UK , 1998, The Lancet.
[33] Irene M. Leigh,et al. Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.
[34] G. Prendergast,et al. The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.
[35] Peer Bork,et al. A superfamily of conserved domains in DNA damage‐ responsive cell cycle checkpoint proteins , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] A. Levine,et al. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[37] S. Fields,et al. Two cellular proteins that bind to wild-type but not mutant p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[38] M. Hollstein,et al. Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.
[39] A. Deisseroth,et al. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. , 1992, Gene.